Literature DB >> 3173499

Radical retropubic prostatectomy with reduced morbidity: an anatomic approach.

P C Walsh1.   

Abstract

The morbidity of radical retropubic prostatectomy for prostate cancer has been reduced through improved understanding of the surgical anatomy of the prostate. Delineation of the anatomy of the dorsal vein complex has led to modifications in the surgical technique that have reduced blood loss and improved surgical exposure. The addition of epidural anesthesia and presurgical donation of autologous blood has limited the need for the homologous transfusion of blood to 2% of the patients and has reduced the frequency of serious perioperative complications such as pulmonary emboli to 0.3%. Delineation of the anatomy of the pelvic plexus and identification of the neurovascular bundles as the macroscopic landmark of the microscopic cavernous nerves have made it possible for the surgeon to make an informed decision at the time of surgery whether the neurovascular bundles can be preserved safely or excised widely with the specimen. In all surgical approaches to prostate cancer, the primary goal must be excision of all tumor; preservation of sexual function should be of secondary concern. These considerations were addressed in the treatment of 320 consecutive patients; 74% of the men are potent postoperatively. It was necessary to excise one neurovascular bundle widely in 49 patients; 69% are potent. In addition to improvements in postoperative sexual function, the incidence of incontinence following surgery has been reduced. The total medical expenses for patients undergoing radical prostatectomy range from $8,500 to $9,500 and are similar to those for external-beam radiotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3173499

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  9 in total

1.  Erectile function outcomes in the current era of anatomic nerve-sparing radical prostatectomy.

Authors:  Arthur L Burnett
Journal:  Rev Urol       Date:  2006

2.  Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice.

Authors:  Andrea Billing; Alexander Buchner; Christian Stief; Alexander Roosen
Journal:  World J Urol       Date:  2014-11-29       Impact factor: 4.226

Review 3.  [Intermediate and high risk prostate cancer patients. Clinical significance of extended lymphadenectomy].

Authors:  D K Osmonov; A Boller; A Aksenov; M Naumann; K P Jünemann
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

Review 4.  Treatment options for male stress urinary incontinence.

Authors:  Jaspreet S Sandhu
Journal:  Nat Rev Urol       Date:  2010-04       Impact factor: 14.432

5.  Modification of retropubic adenomectomy: improved hemostasis and outcome.

Authors:  Ioannis Filiadis; Vasileios Adamopoulos; Erotokritos Konstandinidis
Journal:  Int Urol Nephrol       Date:  2007-01-31       Impact factor: 2.370

Review 6.  Contemporary treatments in prostate cancer focal therapy.

Authors:  Michael Ahdoot; Amir H Lebastchi; Baris Turkbey; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

7.  The effects of retropubic and perineal radical prostatectomy techniques on postoperative urinary continence after surgery: Results of 196 patients.

Authors:  Alper Kafkaslı; Mustafa Yücel Boz; Muhsin Balaban; Rahim Horuz; Ahmet Selimoğlu; Selami Albayrak; Önder Cangüven
Journal:  Turk J Urol       Date:  2013-09

8.  Transplantation of muscle-derived stem cells into the corpus cavernosum restores erectile function in a rat model of cavernous nerve injury.

Authors:  Jang Chun Woo; Woong Jin Bae; Su Jin Kim; Sung Dae Kim; Dong Wan Sohn; Sung Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Young Chul Sung; Sae Woong Kim
Journal:  Korean J Urol       Date:  2011-05-24

9.  Extended salvage pelvic lymph node dissection in patients with recurrent prostate cancer.

Authors:  Daniar K Osmonov; Alexey V Aksenov; Annkathrin Boller; Almut Kalz; Diana Heimann; Isa Janssen; Klaus-Peter Jünemann
Journal:  Adv Urol       Date:  2014-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.